| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPARa |
| Uniprot No | Q07869 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-468aa |
| 氨基酸序列 | MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSCPGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACEGCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSEKAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY |
| 预测分子量 | 56.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PPARα重组蛋白的3篇参考文献及简要摘要：
---
1. **《Functional characterization of recombinant human PPARα subtypes in reporter gene assays》**
*作者：Michalik L. et al.*
**摘要**：研究通过重组技术表达人源PPARα及其亚型，利用报告基因系统验证其对不同配体(如脂肪酸和贝特类药物)的激活能力，揭示了亚型间转录活性的差异。
2. **《Expression and purification of PPARα ligand-binding domain in E. coli for structural studies》**
*作者：Xu H.E. et al.*
**摘要**：报道了在大肠杆菌中高效表达并纯化PPARα配体结合域(LBD)的方法，通过结晶和X射线衍射分析其三维结构，为药物设计提供结构基础。
3. **《PPARα recombinant protein-based screening model for dyslipidemia drug discovery》**
*作者：Goto T. et al.*
**摘要**：构建基于PPARα重组蛋白的高通量筛选模型，评估天然化合物对其活性的调控作用，发现多个潜在调节脂代谢的候选分子。
---
以上文献聚焦于PPARα重组蛋白的表达、结构解析及功能应用，适用于药物开发和分子机制研究。如需具体发表年份或期刊，可进一步补充数据库检索信息。
Peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated nuclear receptor that plays a central role in regulating lipid metabolism, energy homeostasis, and inflammatory responses. As a transcription factor, it forms heterodimers with retinoid X receptor (RXR) and binds to PPAR response elements (PPREs) in the promoter regions of target genes. PPARα is highly expressed in metabolically active tissues such as the liver, heart, and skeletal muscle, where it governs the expression of genes involved in fatty acid oxidation, lipoprotein metabolism, and glucose regulation. Its activation by endogenous ligands (e.g., fatty acids) or synthetic agonists (e.g., fibrates) makes it a therapeutic target for dyslipidemia and metabolic disorders.
Recombinant PPARα protein, produced through genetic engineering in systems like *E. coli* or mammalian cell cultures, retains the functional domains required for ligand binding, DNA interaction, and co-activator recruitment. This engineered protein typically includes affinity tags (e.g., His-tag) for purification and detection. Researchers use it to study PPARα's molecular mechanisms, including ligand-receptor interactions, conformational changes upon activation, and downstream gene regulation. It also serves as a tool for high-throughput drug screening to identify novel agonists or antagonists.
In biomedical research, recombinant PPARα enables *in vitro* studies dissecting its role in metabolic diseases (e.g., atherosclerosis, diabetes, non-alcoholic fatty liver disease) and aging-related processes. Its applications extend to structural biology (e.g., X-ray crystallography) to resolve 3D configurations and optimize drug design. Despite advancements, challenges remain in replicating post-translational modifications present in native tissues, which may affect functional studies. Overall, recombinant PPARα provides a scalable, controlled platform for both basic research and therapeutic development.
×
